This updated review concluded that lithium was effective in reducing the risk of suicide in people with mood disorders such as depression and bipolar disorder. The conclusion reflects the evidence presented and is likely to be reliable.
Study selection
Randomised controlled trials (RCTs) that compared lithium with placebo or another compound in the long-term (>12 weeks) treatment of mood disorders were eligible for inclusion. Participants could be adults or children diagnosed with unipolar depression, bipolar disorder, schizoaffective disorder, dysthymia or rapid cycling disorder. The main outcomes were suicide, deliberate self-harm and all-cause mortality. Studies that recruited participants with a serious concomitant medical disorder were excluded. Some included trials recruited only patients with unipolar depression or bipolar disorder; others included a mix of participants with different disorders. Treatment setting and stage of disease varied widely across trials. Lithium was compared with placebo and 14 other treatments in trials with up to four arms. Other drugs were given in most trials (details in the paper).
Two reviewers independently selected studies for inclusion.
Assessment of study quality
Study quality was assessed by two independent reviewers using Cochrane risk of bias criteria.
Data extraction
Data were extracted to calculate odds ratios (OR) and associated 95% confidence intervals (CI) using Peto's method. Intention-to-treat data were used where possible. Study authors or sponsors were contacted for additional data where necessary.
Data extraction was performed by two independent reviewers.
Methods of synthesis
Pooled Peto odds ratios and 95% CI were derived by meta-analysis. Different head-to-head comparisons were analysed separately. Heterogeneity was assessed visually and using the Ι² and Χ² statistics. Preplanned sensitivity analyses focused on studies in people with unipolar depression and on studies recruiting children and young people aged under 18.
Results of the review
Forty-eight RCTs (6,674 patients) were included. Mean follow-up was 19.1 months (range four to 48 months). Study quality was generally good but some trials did not report details of randomisation and allocation concealment. Twentynine trials had fewer than 100 participants, resulting in few suicide or self-harm events. In sensitivity analyses against placebo, lithium reduced suicide and all-cause mortality but not self harm in patients with unipolar depression. The planned analysis focusing on young people was not possible because of small numbers of events.
